Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Strides Pharma Ranitidine relaunched in US citing acceptable NDMA limits

      Strides Pharma Ranitidine relaunched in US citing acceptable NDMA limits

      Medical Dialogues Bureau9 Nov 2019 9:45 AM IST
      "Strides' Ranitidine tablets 300 mg were within the acceptable limits for NDMA of 96 nanograms per day or 0.32 ppm. Strides Pharma has now completed...
      AstraZeneca CKD anaemia drug Roxadustat shows increased haemoglobin levels in Phase 3 trial

      AstraZeneca CKD anaemia drug Roxadustat shows increased haemoglobin levels in Phase 3 trial

      Medical Dialogues Bureau9 Nov 2019 9:15 AM IST
      New Delhi: AstraZeneca recently presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that Roxadustat significantly...
      Crescita Therapeutics gets USFDA nod for Enhanced Formulation of Pliaglis

      Crescita Therapeutics gets USFDA nod for Enhanced Formulation of Pliaglis

      Medical Dialogues Bureau9 Nov 2019 9:15 AM IST
      New Delhi: Crescita Therapeutics Inc. ("Crescita"), a commercial dermatology company with manufacturing capabilities and a portfolio of...
      Johnson and Johnson seeks European Medicines Agency nod for Ebola Vaccine

      Johnson and Johnson seeks European Medicines Agency nod for Ebola Vaccine

      Medical Dialogues Bureau8 Nov 2019 9:45 AM IST
      JnJ said it submitted two marketing authorization applications to the European Medicines Agency (EMA) for its vaccine regimen targeting the Zaire...
      Penalty levied by SEBI on Jubilant Life Sciences reduced to Rs 5 lakh

      Penalty levied by SEBI on Jubilant Life Sciences reduced to Rs 5 lakh

      Medical Dialogues Bureau8 Nov 2019 9:30 AM IST
      "We have found that the appellant in... Jubilant Life Sciences would be liable for a penalty only on one count i.e. for non-disclosure of the China...
      Fortis Healthcare reports net profit of Rs 124 crore for September quarter

      Fortis Healthcare reports net profit of Rs 124 crore for September quarter

      Medical Dialogues Bureau8 Nov 2019 9:20 AM IST
      "The company continues to witness progressively improving quarters in both the hospitals and the diagnostics business," Fortis Healthcare Board...
      Juul Labs to pull back sales of mint-flavoured nicotine pods in US

      Juul Labs to pull back sales of mint-flavoured nicotine pods in US

      Medical Dialogues Bureau8 Nov 2019 9:00 AM IST
      Juul Labs Inc had said last year it would pull popular flavours such as mango, cucumber and fruit from retail store shelves to reduce surging teenage...
      CDSCO to regulate Adhesives for fixing wigs, scalp cleansing products, artificial nails system, invites comments

      CDSCO to regulate Adhesives for fixing wigs, scalp cleansing products, artificial nails system, invites comments

      Medical Dialogues Bureau7 Nov 2019 5:01 PM IST
      With regard to artificial nails, it has been decided by CDSCO to incorporate a new category named ‘Artificial Nail Systems" in column 3 of the...
      New USFDA warning letters show Glenmark, Lupin, Cadila Healthcare in trouble

      New USFDA warning letters show Glenmark, Lupin, Cadila Healthcare in trouble

      Medical Dialogues Bureau7 Nov 2019 4:20 PM IST
      Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd. and Lupin Ltd. are the latest local medicine makers to be reprimanded by the US Food and Drug...
      Aurobindo Pharma gets 8 USFDA observations for 2 facilities in Hyderabad

      Aurobindo Pharma gets 8 USFDA observations for 2 facilities in Hyderabad

      Medical Dialogues Bureau7 Nov 2019 9:45 AM IST
      The USFDA inspected active pharmaceutical ingredients (API) manufacturing facility (Unit V) at Pashamylaram and API manufacturing facility (Unit VIII)...
      Novartis arm wins USFDA nod for biosimilar Ziextenzo in oncology care

      Novartis arm wins USFDA nod for biosimilar Ziextenzo in oncology care

      Medical Dialogues Bureau7 Nov 2019 9:30 AM IST
      New Delhi: Novartis division, Sandoz recently announced that the US Food and Drug Administration (USFDA) approved its biosimilar ZiextenzoTM...
      Lupin posts Rs 123 crore net loss in Q2

      Lupin posts Rs 123 crore net loss in Q2

      Medical Dialogues Bureau7 Nov 2019 9:15 AM IST
      Lupin said it has agreed to pay Rs 450.06 crore as settlement in connection with the lawsuit in the US and, accordingly, a provision of Rs 379.18...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok